These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22608016)

  • 1. Olmesartan for the prevention or delay of diabetic nephropathy: some considerations.
    Catalá-López F; Martín-Serrano G; Maciá MA; Montero D
    Rev Esp Cardiol (Engl Ed); 2012 Jul; 65(7):678-9; author reply 679-80. PubMed ID: 22608016
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?
    Consuegra-Sánchez L; Sanchis J; Núñez J; Cascón JD; Villegas M; Picó F
    Rev Esp Cardiol (Engl Ed); 2012 Apr; 65(4):378-80. PubMed ID: 21840109
    [No Abstract]   [Full Text] [Related]  

  • 3. Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes.
    Ingelfinger JR
    N Engl J Med; 2011 Mar; 364(10):970-1. PubMed ID: 21388316
    [No Abstract]   [Full Text] [Related]  

  • 4. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.
    Haller H; Ito S; Izzo JL; Januszewicz A; Katayama S; Menne J; Mimran A; Rabelink TJ; Ritz E; Ruilope LM; Rump LC; Viberti G;
    N Engl J Med; 2011 Mar; 364(10):907-17. PubMed ID: 21388309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Porphyria cutanea tarda induced by olmesartan.
    Mas-Vidal A; Coto-Segura P; García-Varona A; Santos-Juanes J
    J Eur Acad Dermatol Venereol; 2010 Aug; 24(8):977-8. PubMed ID: 20015057
    [No Abstract]   [Full Text] [Related]  

  • 6. [In diarrhea of unknown origin also think of olmesartan!].
    Storr M
    MMW Fortschr Med; 2015 Mar; 157(4):34. PubMed ID: 25743974
    [No Abstract]   [Full Text] [Related]  

  • 7. [Sprue-like enteropathy due to olmesartan: a case report].
    Agudo Fernández S
    Gastroenterol Hepatol; 2015 Feb; 38(2):108-9. PubMed ID: 24958550
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients.
    Scholze J; Schaefer A; Kreutz R
    Expert Opin Drug Saf; 2011 Mar; 10(2):185-96. PubMed ID: 21254872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe angioedema associated with olmesartan.
    Vasquez JL; Jaramillo JC; Fernandez C; Enriquez A; Mielgo R
    Ann Allergy Asthma Immunol; 2011 Sep; 107(3):285. PubMed ID: 21875552
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of gender on transition of normo- to microalbuminuria under angiotensin receptor blocker therapy in diabetes.
    Scurt FG; Menne JJ; Korda A; Haller H; Chatzikyrkou C
    J Diabetes; 2020 Nov; 12(11):856-859. PubMed ID: 32755046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olmesartan, microalbuminuria, and type 2 diabetes.
    Fioretto P; Mauer M
    N Engl J Med; 2011 Jun; 364(23):2260-1; author reply 2262-3. PubMed ID: 21651400
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe spruelike enteropathy due to olmesartan.
    Fiorucci G; Puxeddu E; Colella R; Paolo Reboldi G; Villanacci V; Bassotti G
    Rev Esp Enferm Dig; 2014 Feb; 106(2):142-4. PubMed ID: 24852741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Haller H; Viberti GC; Mimran A; Remuzzi G; Rabelink AJ; Ritz E; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Januszewicz A
    J Hypertens; 2006 Feb; 24(2):403-8. PubMed ID: 16508590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sprue-like enteropathy linked to olmesartan.
    Campos Ruiz A; Urtasun Arlegui L; Marra-López Valenciano C
    Rev Esp Enferm Dig; 2016 May; 108(5):292-3. PubMed ID: 26925975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olmesartan, microalbuminuria, and type 2 diabetes.
    Yudkin JS; Lehman R
    N Engl J Med; 2011 Jun; 364(23):2260; author reply 2262-3. PubMed ID: 21651401
    [No Abstract]   [Full Text] [Related]  

  • 16. Olmesartan, microalbuminuria, and type 2 diabetes.
    Lammert A; Krämer BK; Krüger B
    N Engl J Med; 2011 Jun; 364(23):2261; author reply 2262-3. PubMed ID: 21651399
    [No Abstract]   [Full Text] [Related]  

  • 17. Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.
    Ohtomo S; Ito M; Izuhara Y; Van Ypersele De Strihou C; Miyata T
    Nephrology (Carlton); 2008 Dec; 13(6):517-21. PubMed ID: 18363646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan.
    Abe M; Oikawa O; Okada K; Soma M
    J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):159-64. PubMed ID: 25287898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Series: Clinical study from Japan and its reflections; Olmesartan Reducing Incidence of Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT)].
    Imai E
    Nihon Naika Gakkai Zasshi; 2011 Nov; 100(11):3386-92. PubMed ID: 22250438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.